Health Care • Biotechnology: In Vitro & In Vivo Diagnostic Substances
$13.76 ▼ -0.25
(-1.78%)
MKT CAP: $943.6M • VOL: 1.51M
52W L $10 52W H $36
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$12
MEDIAN
$15
MEAN
$16
HIGH
$19
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE QDEL TAPE
QDEL // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $16.65 | $15.82 | 2025-02-14 | $12.52 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $17.34 | $16.24 | 2025-02-06 | $12.93 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $15.69 | $15.14 | 2025-01-29 | $13.21 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $14.04 | — | 2025-01-17 | $13.48 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $12.11 | $13.07 | 2025-01-09 | $12.25 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $16.37 | $14.31 | 2024-12-18 | $11.97 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $13.35 | $13.90 | 2024-12-04 | $12.80 | -4.3% | 48% | C |